Summary
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient populations. It is essential to understand the current disease landscape, the prior research, and the competitive clinical trial environment when posi¬tioning a new clinical trial within the rare disease space. This white paper discusses strategies for accelerating rare disease clinical development by lever¬aging data in a more evidence-based approach to guide the design of a trial; to understand treat¬ment trends; and to identify the best investigators, sites, and patients.
Register to download
Strategies for Accelerating Rare Disease Clinical Development
You may also be interested in:
Capability
ECG Assessments During the Development of Oncology Compounds
Single-center oncology studies performed by dedicated PRA staff, combined with the High Precision QT approach of iCardiac, generates conclusive ECG…
resource
Opportunities in low-level radiocarbon microtracing: applications and new technology
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…
Fact Sheet
The Fundamentals of Human Abuse Potential (HAP) Studies: A 7-Point Checklist
Improving the science of abuse assessment before a drug is marketed is a unified goal for the FDA and pharmaceutical industry. It is the hope that…